IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v6y2015i1d10.1038_ncomms8530.html
   My bibliography  Save this article

The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming

Author

Listed:
  • Liem Phan

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston
    Present address: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.)

  • Ping-Chieh Chou

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Guermarie Velazquez-Torres

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Ismael Samudio

    (The University of Texas MD Anderson Cancer Center)

  • Kenneth Parreno

    (The University of Texas MD Anderson Cancer Center)

  • Yaling Huang

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Chieh Tseng

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Thuy Vu

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Chris Gully

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Chun-Hui Su

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Edward Wang

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Jian Chen

    (The University of Texas MD Anderson Cancer Center)

  • Hyun-Ho Choi

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Enrique Fuentes-Mattei

    (The University of Texas MD Anderson Cancer Center)

  • Ji-Hyun Shin

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Christine Shiang

    (Graduate School of Biomedical Sciences, The University of Texas at Houston
    The University of Texas MD Anderson Cancer Center)

  • Brian Grabiner

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Marzenna Blonska

    (The University of Texas MD Anderson Cancer Center)

  • Stephen Skerl

    (The University of Texas MD Anderson Cancer Center)

  • Yiping Shao

    (The University of Texas MD Anderson Cancer Center)

  • Dianna Cody

    (The University of Texas MD Anderson Cancer Center)

  • Jorge Delacerda

    (The University of Texas MD Anderson Cancer Center)

  • Charles Kingsley

    (The University of Texas MD Anderson Cancer Center)

  • Douglas Webb

    (The University of Texas MD Anderson Cancer Center)

  • Colin Carlock

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

  • Zhongguo Zhou

    (The University of Texas MD Anderson Cancer Center)

  • Yun-Chih Hsieh

    (The University of Texas MD Anderson Cancer Center)

  • Jaehyuk Lee

    (The University of Texas MD Anderson Cancer Center)

  • Andrew Elliott

    (The University of Texas MD Anderson Cancer Center)

  • Marc Ramirez

    (The University of Texas MD Anderson Cancer Center)

  • Jim Bankson

    (The University of Texas MD Anderson Cancer Center)

  • John Hazle

    (The University of Texas MD Anderson Cancer Center)

  • Yongxing Wang

    (The University of Texas MD Anderson Cancer Center)

  • Lei Li

    (The University of Texas MD Anderson Cancer Center)

  • Shaofan Weng

    (The University of Texas MD Anderson Cancer Center)

  • Nibal Rizk

    (The University of Texas MD Anderson Cancer Center)

  • Yu Ye Wen

    (The University of Texas MD Anderson Cancer Center)

  • Xin Lin

    (The University of Texas MD Anderson Cancer Center)

  • Hua Wang

    (The University of Texas MD Anderson Cancer Center)

  • Huamin Wang

    (The University of Texas MD Anderson Cancer Center)

  • Aijun Zhang

    (Methodist Hospital Research Institute)

  • Xuefeng Xia

    (Methodist Hospital Research Institute)

  • Yun Wu

    (The University of Texas MD Anderson Cancer Center)

  • Mouhammed Habra

    (The University of Texas MD Anderson Cancer Center)

  • Wei Yang

    (The University of Texas MD Anderson Cancer Center)

  • Lajos Pusztai

    (The University of Texas MD Anderson Cancer Center)

  • Sai-Ching Yeung

    (The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center)

  • Mong-Hong Lee

    (The University of Texas MD Anderson Cancer Center
    Graduate School of Biomedical Sciences, The University of Texas at Houston)

Abstract

Extensive reprogramming of cellular energy metabolism is a hallmark of cancer. Despite its importance, the molecular mechanism controlling this tumour metabolic shift remains not fully understood. Here we show that 14-3-3σ regulates cancer metabolic reprogramming and protects cells from tumorigenic transformation. 14-3-3σ opposes tumour-promoting metabolic programmes by enhancing c-Myc poly-ubiquitination and subsequent degradation. 14-3-3σ demonstrates the suppressive impact on cancer glycolysis, glutaminolysis, mitochondrial biogenesis and other major metabolic processes of tumours. Importantly, 14-3-3σ expression levels predict overall and recurrence-free survival rates, tumour glucose uptake and metabolic gene expression in breast cancer patients. Thus, these results highlight that 14-3-3σ is an important regulator of tumour metabolism, and loss of 14-3-3σ expression is critical for cancer metabolic reprogramming. We anticipate that pharmacologically elevating the function of 14-3-3σ in tumours could be a promising direction for targeted anticancer metabolism therapy development in future.

Suggested Citation

  • Liem Phan & Ping-Chieh Chou & Guermarie Velazquez-Torres & Ismael Samudio & Kenneth Parreno & Yaling Huang & Chieh Tseng & Thuy Vu & Chris Gully & Chun-Hui Su & Edward Wang & Jian Chen & Hyun-Ho Choi , 2015. "The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming," Nature Communications, Nature, vol. 6(1), pages 1-16, November.
    • Handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8530
    DOI: 10.1038/ncomms8530
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms8530
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms8530?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8530. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.